Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer |
| |
Authors: | Annicotte Jean-Sébastien Iankova Irena Miard Stéphanie Fritz Vanessa Sarruf David Abella Anna Berthe Marie-Laurence Noël Danièle Pillon Arnaud Iborra François Dubus Pierre Maudelonde Thierry Culine Stéphane Fajas Lluis |
| |
Affiliation: | Equipe Avenir, INSERM U540, 60 rue de Navacelles, F-34090 Montpellier, France. |
| |
Abstract: | Peroxisome proliferator-activated receptor gamma (PPARgamma) might not be permissive to ligand activation in prostate cancer cells. Association of PPARgamma with repressing factors or posttranslational modifications in PPARgamma protein could explain the lack of effect of PPARgamma ligands in a recent randomized clinical trial. Using cells and prostate cancer xenograft mouse models, we demonstrate in this study that a combination treatment using the PPARgamma agonist pioglitazone and the histone deacetylase inhibitor valproic acid is more efficient at inhibiting prostate tumor growth than each individual therapy. We show that the combination treatment impairs the bone-invasive potential of prostate cancer cells in mice. In addition, we demonstrate that expression of E-cadherin, a protein involved in the control of cell migration and invasion, is highly up-regulated in the presence of valproic acid and pioglitazone. We show that E-cadherin expression responds only to the combination treatment and not to single PPARgamma agonists, defining a new class of PPARgamma target genes. These results open up new therapeutic perspectives in the treatment of prostate cancer. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|